Fig. 1: ABCC1 modulates Venetoclax sensitivity in AML cells.

A Schematic representation of the CRISPR/Cas9-based competitive proliferation assay. Each ABC transporter gene is targeted with two sgRNAs in Cas9-expressing MOLM-13 cells. Cells were divided and treated with DMSO or Venetoclax. The percentage of sgRNA-expressing cells (IRFP670⁺) was monitored over time and the area under the curve (AUC) was determined for each sgRNA. The corresponding flow cytometric gating strategy for IRFP670⁺ cells is depicted in Supplementary Fig. 6A. B The AUC after 30 days of treatment of DMSO-treated MOLM-13-Cas9 cells expressing sgRNAs targeting ABC transporters is plotted against the AUC (30 days) of cells treated with 1 nM Venetoclax (left) or 50 nM Cytarabine (right). n = 4 experimental replicates with 2 different sgRNAs per gene. C Competitive proliferation assay of MOLM-13-Cas9 cells treated with 1 nM Venetoclax (left; n = 2 experimental replicates) and HL-60-Cas9 cells treated with 100 nM Venetoclax (right; n = 3 experimental replicates) for 30 days. Percentages of sgRNA/IRFP670+ cells were normalized to day 0 of treatment and to DMSO controls. Data are presented as mean values ± SD. B, C Source data are provided as a Source Data file.